Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF

Molecular Pharmaceutics

Volumn 7, Issue 2, 2010, Pages 543-556

  Tai, Wanyi ^a   Qin, Bin ^a   Cheng, Kun ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Breast cancer; Dual silencing; HER 2; Invasiveness; SiRNA; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SMALL INTERFERING RNA; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SPREADING; CELL STRUCTURE; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SILENCING; GENE THERAPY; HUMANS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77950584606     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp9002514     Document Type: Article

References (61)

1. Greenlee, R. T.; Hill-Harmon, M. B.; Murray, T.; Thun, M. Cancer statistics, 2001 Ca-Cancer J. Clin. 2001, 51, 15-36
2. Stoff-Khalili, M. A.; Dall, P.; Curiel, D. T. Gene therapy for carcinoma of the breast Cancer Gene Ther. 2006, 13, 633-647
3. Takahashi, S.; Ito, Y.; Hatake, K.; Sugimoto, Y. Gene therapy for breast cancer.-Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital Breast Cancer 2006, 13, 8-15
4. Bartsch, R.; Wenzel, C.; Zielinski, C. C.; Steger, G. G. HER-2-positive breast cancer: hope beyond trastuzumab BioDrugs 2007, 21, 69-77
5. Engel, R. H.; Kaklamani, V. G. HER2-positive breast cancer: current and future treatment strategies Drugs 2007, 67, 1329-1341
6. Yang, G.; Cai, K. Q.; Thompson-Lanza, J. A.; Bast, R. C., Jr.; Liu, J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression J. Biol. Chem. 2004, 279, 4339-4345
7. Faltus, T.; Yuan, J.; Zimmer, B.; Kramer, A.; Loibl, S.; Kaufmann, M.; Strebhardt, K. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells Neoplasia 2004, 6, 786-795
8. Choudhury, A.; Charo, J.; Parapuram, S. K.; Hunt, R. C.; Hunt, D. M.; Seliger, B.; Kiessling, R. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines Int. J. Cancer 2004, 108, 71-77
9. Hobday, T. J.; Perez, E. A. Molecularly targeted therapies for breast cancer Cancer Control 2005, 12, 73-81
10. Sobel, M.; Hashimoto, J.; Arnoczky, S. P.; Bohne, W. H. The microvasculature of the sesamoid complex: its clinical significance Foot Ankle 1992, 13, 359-363
11. Toi, M.; Inada, K.; Suzuki, H.; Tominaga, T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression Breast Cancer Res. Treat. 1995, 36, 193-204
12. Uzzan, B.; Nicolas, P.; Cucherat, M.; Perret, G. Y. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis Cancer Res. 2004, 64, 2941-2955
13. Hansen, S.; Grabau, D. A.; Sorensen, F. B.; Bak, M.; Vach, W.; Rose, C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients Clin. Cancer Res. 2000, 6, 139-146
14. Weis, S. M.; Cheresh, D. A. Pathophysiological consequences of VEGF-induced vascular permeability Nature 2005, 437, 497-504
15. Davidoff, A. M.; Nathwani, A. C. Antiangiogenic gene therapy for cancer treatment Current Hematol. Rep. 2004, 3, 267-273
16. Sledge, G. W.; Rugo, H. S.; Burstein, H. J. The role of angiogenesis inhibition in the treatment of breast cancer Clin. Adv. Hematol. Oncol. 2006, 4 (Suppl. 21) 1-12
17. Zelnak, A. B.; O'Regan, R. M. Targeting angiogenesis in advanced breast cancer BioDrugs 2007, 21, 209-214
18. Linderholm, B.; Andersson, J.; Lindh, B.; Beckman, L.; Erlanson, M.; Edin, K.; Tavelin, B.; Grankvist, K.; Henriksson, R. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment Eur. J. Cancer 2004, 40, 33-42
19. Finkenzeller, G.; Weindel, K.; Zimmermann, W.; Westin, G.; Marme, D. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1 Angiogenesis 2004, 7, 59-68
20. Konecny, G. E.; Meng, Y. G.; Untch, M.; Wang, H. J.; Bauerfeind, I.; Epstein, M.; Stieber, P.; Vernes, J. M.; Gutierrez, J.; Hong, K.; Beryt, M.; Hepp, H.; Slamon, D. J.; Pegram, M. D. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clin. Cancer Res. 2004, 10, 1706-1716
21. Le, X. F.; Mao, W.; Lu, C.; Thornton, A.; Heymach, J. V.; Sood, A. K.; Bast, R. C., Jr. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2 Cell Cycle 2008, 7, 3747-3758
22. Pegram, M.; Chan, D.; Dichmann, R.; Tan-Chiu, E.; Yeon, C.; Durna, L.; Lin, L.; Slamon, D. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer Breast Cancer Res. Treat. 2006, 100, S28-29
23. Pegram, M. D.; Reese, D. M. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor Semin. Oncol. 2002, 29, 29-37
24. Cheng, K.; Mahato, R. I. Gene modulation for treating liver fibrosis Crit. Rev. Ther. Drug Carrier Syst. 2007, 24, 93-146 (Pubitemid 47324848)
25. Mahato, R. I.; Cheng, K.; Guntaka, R. V. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA Expert Opin. Drug Delivery 2005, 2, 3 - 28 (Pubitemid 40123880)
26. Cheng, K.; Yang, N.; Mahato, R. I. TGF-beta1 Gene Silencing for Treating Liver Fibrosis Mol. Pharmaceutics 2009, 6, 772-779
27. Cheng, K.; Fraga, D.; Zhang, C.; Kotb, M.; Gaber, A. O.; Guntaka, R. V.; Mahato, R. I. Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets Gene Ther. 2004, 11, 1105-1116 (Pubitemid 39117306)
28. Ma, L.; Teruya-Feldstein, J.; Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer Nature 2007, 449, 682-688 (Pubitemid 47552092)
29. Sithanandam, G.; Fornwald, L. W.; Fields, J.; Anderson, L. M. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549 Oncogene 2005, 24, 1847-1859 (Pubitemid 40462787)
30. Pouliot, N.; Connolly, L. M.; Moritz, R. L.; Simpson, R. J.; Burgess, A. W. Colon cancer cells adhesion and spreading on autocrine laminin-10 is mediated by multiple integrin receptors and modulated by EGF receptor stimulation Exp. Cell Res. 2000, 261, 360-371 (Pubitemid 32010232)
31. Charboneau, A. L.; Singh, V.; Yu, T.; Newsham, I. F. Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells Int. J. Cancer 2002, 100, 181-188 (Pubitemid 34666192)
32. Takei, Y.; Kadomatsu, K.; Yuzawa, Y.; Matsuo, S.; Muramatsu, T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics Cancer Res. 2004, 64, 3365 - 3370 (Pubitemid 38657905)
33. Petit, A. M.; Rak, J.; Hung, M. C.; Rockwell, P.; Goldstein, N.; Fendly, B.; Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am. J. Pathol. 1997, 151, 1523-1530 (Pubitemid 27527914)
34. Laughner, E.; Taghavi, P.; Chiles, K.; Mahon, P. C.; Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression Mol. Cell. Biol. 2001, 21, 3995-4004
35. Eccles, S. A. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis J. Mammary Gland Biol. Neoplasia 2001, 6, 393-406
36. Lieberthal, J. G.; Kaminsky, M.; Parkhurst, C. N.; Tanese, N. The role of YY1 in reduced HP1 alpha gene expression in invasive human breast cancer cells Breast Cancer Res. 2009, 11, R42
37. Liang, Y.; Brekken, R. A.; Hyder, S. M. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones Endocr.-Relat. Cancer 2006, 13, 905-919
38. Ge, Y. L.; Zhang, X.; Zhang, J. Y.; Hou, L.; Tian, R. H. The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells Int. Immunopharmacol. 2009, 9, 389-395
39. Lee, T. H.; Seng, S.; Sekine, M.; Hinton, C.; Fu, Y.; Avraham, H. K.; Avraham, S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1 PLoS Med. 2007, 4 e186
40. Price, D. J.; Miralem, T.; Jiang, S.; Steinberg, R.; Avraham, H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells Cell Growth Differ. 2001, 12, 129-135
41. Sledge, G. W., Jr. VEGF-targeting therapy for breast cancer J. Mammary Gland Biol. Neoplasia 2005, 10, 319-323
42. Foekens, J. A.; Peters, H. A.; Grebenchtchikov, N.; Look, M. P.; Meijer-van Gelder, M. E.; Geurts-Moespot, A.; van der Kwast, T. H.; Sweep, C. G.; Klijn, J. G. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res. 2001, 61, 5407-5414
43. Roh, H.; Pippin, J.; Boswell, C.; Drebin, J. A. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu J. Surg. Res. 1998, 77, 85-90
44. Lu, J. J.; Langer, R.; Chen, J. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery Mol. Pharmaceutics 2009, 6, 763-771
45. Bagheri-Yarmand, R.; Vadlamudi, R. K.; Wang, R. A.; Mendelsohn, J.; Kumar, R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis J. Biol. Chem. 2000, 275, 39451-39457
46. Wen, X. F.; Yang, G.; Mao, W.; Thornton, A.; Liu, J.; Bast, R. C., Jr.; Le, X. F. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy Oncogene 2006, 25, 6986-6996
47. Eccles, S. A.; Welch, D. R. Metastasis: recent discoveries and novel treatment strategies Lancet 2007, 369, 1742-1757
48. Timoshenko, A. V.; Rastogi, S.; Lala, P. K. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells Br. J. Cancer 2007, 97, 1090-1098
49. De Corte, V.; De Potter, C.; Vandenberghe, D.; Van Laerebeke, N.; Azam, M.; Roels, H.; Mareel, M.; Vandekerckhove, J. A 50 kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of Neu/HER-2, in human SK-BR-3 mammary cancer cells J. Cell Sci. 1994, 107, 405-416
50. Wiechen, K.; Dietel, M. c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells Int. J. Cancer 1995, 63, 604-608
51. Chen, X.; Zheng, Y.; Zhu, J.; Jiang, J.; Wang, J. p73 is transcriptionally regulated by DNA damage, p53, and p73 Oncogene 2001, 20, 769-774
52. Butler, T. P.; Gullino, P. M. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma Cancer Res. 1975, 35, 512-516
53. Cominetti, M. R.; Martin, A. C.; Ribeiro, J. U.; Djaafri, I.; Fauvel-Lafeve, F.; Crepin, M.; Selistre-de-Araujo, H. S. Inhibition of platelets and tumor cell adhesion by the disintegrin domain of human ADAM9 to collagen I under dynamic flow conditions Biochimie 2009, 91, 1045-1052
54. Yu, D.; Hamada, J.; Zhang, H.; Nicolson, G. L.; Hung, M. C. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products Oncogene 1992, 7, 2263-2270
55. Spangenberg, C.; Lausch, E. U.; Trost, T. M.; Prawitt, D.; May, A.; Keppler, R.; Fees, S. A.; Reutzel, D.; Bell, C.; Schmitt, S.; Schiffer, I. B.; Weber, A.; Brenner, W.; Hermes, M.; Sahin, U.; Tureci, O.; Koelbl, H.; Hengstler, J. G.; Zabel, B. U. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions Cancer Res. 2006, 66, 3715-3725
56. Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling-in control of vascular function Nat. Rev. 2006, 7, 359-371
57. Mercurio, A. M.; Lipscomb, E. A.; Bachelder, R. E. Non-angiogenic functions of VEGF in breast cancer J. Mammary Gland Biol. Neoplasia 2005, 10, 283-290
58. Schneider, B. P.; Sledge, G. W., Jr. Drug insight: VEGF as a therapeutic target for breast cancer Nat. Clin. Pract. Oncol. 2007, 4, 181-189
59. Zhang, W.; Ran, S.; Sambade, M.; Huang, X.; Thorpe, P. E. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model Angiogenesis 2002, 5, 35-44
60. Liang, Y.; Hyder, S. M. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects Endocrinology 2005, 146, 3632-3641
61. Bruns, C. J.; Liu, W.; Davis, D. W.; Shaheen, R. M.; McConkey, D. J.; Wilson, M. R.; Bucana, C. D.; Hicklin, D. J.; Ellis, L. M. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases Cancer 2000, 89, 488-499